Jazz Pharmaceuticals
JAZZ
468 hedge funds and large institutions have $8.95B invested in Jazz Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 59 funds opening new positions, 147 increasing their positions, 166 reducing their positions, and 42 closing their positions.
40% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 42
21% more capital inflows, than outflows
Capital inflows: $759M | Capital outflows: $628M
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
1% more funds holding
Funds holding: 462 → 468 (+6)
0.14% less ownership
Funds ownership: 92.17% → 92.03% (-0.14%)
11% less repeat investments, than reductions
Existing positions increased: 147 | Existing positions reduced: 166
54% less call options, than puts
Call options by funds: $20.3M | Put options by funds: $44M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$91M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$58.2M |
| 3 |
SC
Samlyn Capital
New York
|
+$40.7M |
| 4 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
+$37M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$34.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$79.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$56.9M |
| 3 |
AC
Armistice Capital
New York
|
-$29.9M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$28.2M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$26.6M |
JAZZ Hedge Fund Activity: Q2 2022 in Review
468 of the 5,962 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q2 2022, worth a combined $8.95B — up 0.9% from $8.87B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new JAZZ positions and 42 closed out — a net gain of 17 holders — while 147 added to existing stakes and 166 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $91M. The largest seller was Canada Pension Plan Investment Board, cutting an estimated $79.1M.
- 468 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q2 2022, up from 462 in Q1 2022.
- Funds reported $8.95B of Jazz Pharmaceuticals stock for Q2 2022, up 0.9% quarter-over-quarter.
- 59 funds opened new Jazz Pharmaceuticals positions in Q2 2022 and 42 closed out, a net change of +17 holders.
- The largest Jazz Pharmaceuticals buyer in Q2 2022 was Farallon Capital Management, an estimated $91M added.
- The largest Jazz Pharmaceuticals seller in Q2 2022 was Canada Pension Plan Investment Board, an estimated $79.1M sold.
Based on aggregated 13F filings for Q2 2022.